LCTX
Lineage Cell Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.02 EPS, $4.57M rev
Last earnings +1.5% on 2026-05-12
$1.28
▲ +4.92%$1.28▲ +33.33%
over 1Y
L $0.90EODHDH $1.96
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.9%
1W+1.6%
1M-1.5%
3M-14.1%
YTD-22.0%
1Y+33.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Revenue grew 53.2% YoY; but unprofitable (net margin -436.5%).
Revenue (FY2025) $14.6M · FY2025
Lineage Cell Therapeutics, Inc. shows $14.6M in FY2025 revenue (+53.2% YoY), a -436.5% net margin, and -142.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $4.34M | $14.7M | $8.95M | $9.50M | $14.6M |
| Gross profit | $2.92M | $14.0M | $8.27M | — | — |
| Operating income | -$49.2M | -$22.5M | -$24.7M | -$21.5M | -$36.6M |
| Net income | -$43.0M | -$26.3M | -$21.5M | -$18.6M | -$63.5M |
| Diluted EPS | — | -$0.15 | -$0.12 | -$0.09 | -$0.28 |
| Net margin | -991.0% | -178.7% | -240.2% | -195.9% | -436.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$278M
EV / EBITDA—
EV / Sales19.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-19.9%
FCF yield-6.1%
Quality & risk
ROIC (est.)-64.9%
Free cash flow-$19.4M
Total debt—
Net cash$40.8M
Altman Z-Score-3.48 distress
Piotroski F-Score3/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+9.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-092026-06-12open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗ARSPeriod ending 2025-12-312026-04-29open ↗DEFA14AFiling2026-04-29open ↗DEF 14APeriod ending 2026-04-292026-04-29open ↗EFFECTFiling2026-03-23open ↗CORRESPFiling2026-03-19open ↗UPLOADFiling2026-03-16open ↗4Period ending 2026-03-122026-03-12open ↗S-3Filing2026-03-11open ↗8-KPeriod ending 2026-03-112026-03-11open ↗
Frequently asked
- Is Lineage Cell Therapeutics, Inc. (LCTX) a buy?
- LCTX currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 53.2% YoY; but unprofitable (net margin -436.5%).
- What is Lineage Cell Therapeutics, Inc.'s quality score?
- LCTX scores 37.15686274509804/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000876343, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 6:16:05 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.